Veterinary and Comparative Oncology Veterinary and Comparative Oncology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

---
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page E16-E22, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 16, 2017 Category: Veterinary Research Source Type: research

Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page E30-E37, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 15, 2017 Category: Veterinary Research Source Type: research

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page E23-E29, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 15, 2017 Category: Veterinary Research Source Type: research

---
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page E30-E37, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 15, 2017 Category: Veterinary Research Source Type: research

---
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page E23-E29, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 15, 2017 Category: Veterinary Research Source Type: research

Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma
Efficacious therapies for measurable metastatic canine osteosarcoma (OSA) are generally lacking. Preliminary retrospective studies suggested that approximately 50% of dogs with measurable metastatic OSA experienced clinical benefit (objective response or clinically meaningful disease stabilisation) following toceranib (TOC) treatment. The purpose of this clinical trial was to prospectively evaluate the clinical outcome following TOC treatment in dogs with measurable pulmonary metastatic OSA. A secondary goal was to identify potential biomarkers of clinical benefit by measuring changes in plasma vascular endothelial growth ...
Source: Veterinary and Comparative Oncology - June 15, 2017 Category: Veterinary Research Authors: T. Laver, C. A. London, D. M. Vail, B. J. Biller, J. Coy, D. H. Thamm Tags: ORIGINAL ARTICLE Source Type: research

Apoptotic intrinsic pathway proteins predict survival in canine cutaneous mast cell tumours
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page E38-E44, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 13, 2017 Category: Veterinary Research Source Type: research

---
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page E38-E44, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 13, 2017 Category: Veterinary Research Source Type: research

In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page 148-158, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 6, 2017 Category: Veterinary Research Source Type: research

---
Veterinary and Comparative Oncology,Volume 16, Issue 1, Page 148-158, March 2018. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 6, 2017 Category: Veterinary Research Source Type: research

Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma
Temozolomide (TMZ) is an alkylating agent previously used in conjunction with doxorubicin (DOX) to treat dogs with relapsed lymphoma. However, there are very limited data for this drug when used as single agent. The aim of this retrospective study was to evaluate the efficacy and toxicity of TMZ in dogs with relapsed multicentric lymphoma that failed multi‐agent chemotherapy protocols, and compare the outcome to a group of dogs receiving the same drug in combination with DOX. Twenty‐six patients were included in the TMZ group and 11 in the TMZ/DOX group. Responses were evaluated via retrospective review of the medical ...
Source: Veterinary and Comparative Oncology - June 1, 2017 Category: Veterinary Research Authors: E. Treggiari, J. W. Elliott, S. J. Baines, L. Blackwood Tags: ORIGINAL ARTICLE Source Type: research

Clinicopathologic features of lingual canine T ‐zone lymphoma
In this study, we characterize the clinical presentation, diagnostic features and patient outcomes of 12 dogs with lingual TZL. (Source: Veterinary and Comparative Oncology)
Source: Veterinary and Comparative Oncology - June 1, 2017 Category: Veterinary Research Authors: L. J. Harris, E. D. Rout, K. L. Hughes, J. D. Labadie, B. Boostrom, J. A. Yoshimoto, C. M. Cannon, P. R. Avery, E.J. Ehrhart, A. C. Avery Tags: ORIGINAL ARTICLE Source Type: research

Linac ‐based stereotactic radiation therapy for canine non‐lymphomatous nasal tumours: 29 cases (2013‐2016)
Twenty‐nine dogs were treated with linac‐based stereotactic radiation therapy (SRT) for non‐lymphomatous nasal tumours. Only dogs with a follow‐up time >365 days were included in this retrospective analysis. No dogs had evidence of distant metastasis at diagnosis. Treatment was planned and a total of 30 Gy in 3 daily 10 Gy fractions was delivered using intensity‐modulation, cone‐beam CT‐based image guidance and a robotic treatment couch. Clinical signs improved in all cases. Nineteen dogs had CT scans 3‐4 months post‐SRT and all had partial or complete tumour response. Minimal acute toxicities were det...
Source: Veterinary and Comparative Oncology - June 1, 2017 Category: Veterinary Research Authors: T. L. Gieger, M. W. Nolan Tags: ORIGINAL ARTICLE Source Type: research

Patient characteristics, prognostic factors and outcome of dogs with high ‐grade primary mediastinal lymphoma
The goals of this retrospective study were to determine the patient characteristics of dogs with high‐grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow‐up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T‐cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization (WHO) lymphoma c...
Source: Veterinary and Comparative Oncology - June 1, 2017 Category: Veterinary Research Authors: E. L. Moore, W. Vernau, R. B. Rebhun, K. A. Skorupski, J. H. Burton Tags: ORIGINAL ARTICLE Source Type: research

Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas
We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation. Overall and disease‐specific survival times were estimated. Thirty dogs were palliated, 22 dogs were treated with RT and 20 with RT + TMZ. Complete and partial responses were observed in 63.2% and 90.9% of patients in the RT and RT + TMZ arms, respectively, that were alive at 1 year. Median survival in the palliation arm was 94 days (95% conformity index [CI] 87÷101). Median survivals of the RT arm (383 days, 95% CI 276÷490) and RT+TM...
Source: Veterinary and Comparative Oncology - June 1, 2017 Category: Veterinary Research Authors: M. Dolera, L. Malfassi, C. Bianchi, N. Carrara, S. Finesso, S. Marcarini, G. Mazza, S. Pavesi, M. Sala, G. Urso Tags: ORIGINAL ARTICLE Source Type: research